David N. Gill - 05 Oct 2021 Form 4 Insider Report for Strongbridge Biopharma plc

Reporting relationship: Director
Issuer ticker: N/A
Reported as of: 05 Oct 2021
Net transaction value: $0
SEC form: 4
Accepted by SEC: 06 Oct 2021, 19:41:01 UTC
Prior SEC filing: 05 Oct 2021
Next SEC filing: 26 Jan 2022
Source filing: View source filing
Reporting owner signature: /s/ Judith Goldberg, as attorney-in-fact

Key filing fact

David N. Gill filed Form 4 for Strongbridge Biopharma plc on 06 Oct 2021.

Key facts

This page summarizes David N. Gill's Form 4 filing for Strongbridge Biopharma plc.
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 06 Oct 2021, 19:41.

Change

Previous filing in this sequence was filed on 05 Oct 2021.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

SBBP transaction

Ordinary Shares

Disposed to Issuer

Transaction value
Shares: -78,058
Change %: -100%
Price
Shares after: 0
Date: 05 Oct 2021
Ownership: Direct
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

Ordinary shares of Issuer were converted into shares of common stock of Xeris Biopharma Holdings, Inc. ("HoldCo") pursuant to the Transaction Agreement (the "Agreement"), dated May 24, 2021, among the Issuer, Xeris Pharmaceuticals, Inc., HoldCo and Wells MergerSub, Inc. Under the Agreement, each ordinary share of Issuer was exchanged for 0.784 of a share of HoldCo common stock, and cash in lieu of fractional shares, plus one contingent value right (a "CVR") worth up to an additional $1.00, payable in cash, HoldCo common stock or a combination thereof at HoldCo's sole election.